Ocuphire Pharma (OCUP) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OCUP vs. MCRB, RANI, ANRO, RMTI, OPTN, ALLK, DERM, ACET, PDSB, and PRTGShould you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Seres Therapeutics (MCRB), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), Rockwell Medical (RMTI), OptiNose (OPTN), Allakos (ALLK), Journey Medical (DERM), Adicet Bio (ACET), PDS Biotechnology (PDSB), and Portage Biotech (PRTG). These companies are all part of the "pharmaceutical preparations" industry. Ocuphire Pharma vs. Seres Therapeutics Rani Therapeutics Alto Neuroscience Rockwell Medical OptiNose Allakos Journey Medical Adicet Bio PDS Biotechnology Portage Biotech Seres Therapeutics (NASDAQ:MCRB) and Ocuphire Pharma (NASDAQ:OCUP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment. Do institutionals and insiders hold more shares of MCRB or OCUP? 59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Ocuphire Pharma shares are owned by institutional investors. 5.1% of Seres Therapeutics shares are owned by company insiders. Comparatively, 8.7% of Ocuphire Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor MCRB or OCUP? Seres Therapeutics received 491 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. Likewise, 72.13% of users gave Seres Therapeutics an outperform vote while only 69.81% of users gave Ocuphire Pharma an outperform vote. CompanyUnderperformOutperformSeres TherapeuticsOutperform Votes52872.13% Underperform Votes20427.87% Ocuphire PharmaOutperform Votes3769.81% Underperform Votes1630.19% Which has higher valuation and earnings, MCRB or OCUP? Ocuphire Pharma has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ocuphire Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$374K331.97-$113.72M-$0.60-1.37Ocuphire Pharma$16.45M0.00-$9.99M-$0.49N/A Does the media prefer MCRB or OCUP? In the previous week, Seres Therapeutics had 3 more articles in the media than Ocuphire Pharma. MarketBeat recorded 7 mentions for Seres Therapeutics and 4 mentions for Ocuphire Pharma. Ocuphire Pharma's average media sentiment score of 0.13 beat Seres Therapeutics' score of -0.27 indicating that Ocuphire Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ocuphire Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, MCRB or OCUP? Seres Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Ocuphire Pharma has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Is MCRB or OCUP more profitable? Seres Therapeutics has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -85.75%. Seres Therapeutics' return on equity of 0.00% beat Ocuphire Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A N/A -46.67% Ocuphire Pharma -85.75%-30.19%-27.55% Do analysts prefer MCRB or OCUP? Seres Therapeutics currently has a consensus price target of $5.08, indicating a potential upside of 520.07%. Ocuphire Pharma has a consensus price target of $16.00, indicating a potential upside of 0.00%. Given Seres Therapeutics' higher possible upside, equities analysts clearly believe Seres Therapeutics is more favorable than Ocuphire Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Ocuphire Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummarySeres Therapeutics and Ocuphire Pharma tied by winning 9 of the 18 factors compared between the two stocks. Ad Porter & CompanyThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUP vs. The Competition Export to ExcelMetricOcuphire PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.33M$7.12B$5.36B$8.41BDividend YieldN/A8.77%5.22%4.20%P/E Ratio-2.3916.07131.5917.70Price / SalesN/A258.251,438.8478.39Price / CashN/A50.1639.0633.56Price / BookN/A5.674.744.57Net Income-$9.99M$151.16M$115.35M$225.37M Ocuphire Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCUPOcuphire Pharma2.2617 of 5 starsN/A$16.00+∞N/A$30.33M$16.45M-2.3914High Trading VolumeMCRBSeres Therapeutics3.8492 of 5 stars$0.70-1.4%$5.08+621.1%-46.0%$119.97M$126.32M-0.60233Upcoming EarningsRANIRani Therapeutics3.2116 of 5 stars$2.34-2.1%$11.71+400.6%+18.4%$117.98M$2.72M-1.98110ANROAlto Neuroscience2.433 of 5 stars$4.37+5.8%$24.40+458.4%N/A$117.48M$210,000.000.00N/AShort Interest ↑Analyst RevisionHigh Trading VolumeRMTIRockwell Medical4.1836 of 5 stars$3.75+3.9%$9.00+140.0%+118.9%$116.36M$83.61M-22.06300OPTNOptiNose4.0505 of 5 stars$0.77-2.5%$4.00+418.5%-40.9%$116.31M$70.99M-2.14190Positive NewsALLKAllakos4.7379 of 5 stars$1.31+10.1%$1.67+27.2%-32.2%$115.99MN/A-0.56131Short Interest ↓Positive NewsHigh Trading VolumeDERMJourney Medical3.7373 of 5 stars$5.76+6.3%$9.38+62.8%N/A$115.28M$77.68M-288.0090Upcoming EarningsShort Interest ↓ACETAdicet Bio3.2656 of 5 stars$1.40-1.4%$7.50+435.7%+3.8%$115.04M$24.99M-0.5590Positive NewsPDSBPDS Biotechnology1.2239 of 5 stars$3.12+0.3%$14.25+356.7%-23.5%$114.44MN/A-2.5620PRTGPortage Biotech2.0722 of 5 stars$6.36+2.9%$120.00+1,786.8%-85.5%$113.21MN/A-0.146Positive News Related Companies and Tools Related Companies Seres Therapeutics Alternatives Rani Therapeutics Alternatives Alto Neuroscience Alternatives Rockwell Medical Alternatives OptiNose Alternatives Allakos Alternatives Journey Medical Alternatives Adicet Bio Alternatives PDS Biotechnology Alternatives Portage Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCUP) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.